Volkin, Rakesh Srivastava Ph.d. Named KU’s Second, Third Eminent Scholars
Kansas Bioscience Authority Commits $4.3 Million to Support Professors A prominent pharmaceutical scientist with 20 years of industrial research and development experience joined the KU faculty earlier this month, thanks in part to a five-year, $2.5 million financial commitment from the Kansas Bioscience Authority. David Volkin comes to KU from Centocor R&D, a subsidiary of […]
Protein that turns Normal Cells into Cancer Stem Cells Offers Target to Fight Colon Cancer
Colon cancer is a global killer. Each year more than one million people worldwide are diagnosed with it; more than half a million die from it. If diagnosed early enough the standard treatment involves surgery, chemotherapy, radiation or targeted drug therapy to destroy the tumors. In many cases this may work. But in some cases, […]